AERx iDMS pulmonary insulin: Phase III data

Interim 12-month results from a Phase III trial of AERx iDMS pulmonary insulin showed delayed post-meal plasma glucose suppression in Type I diabetics compared to subcutaneous insulin. Nighttime plasm...